Well, I was thinking the other day that given the fiasco in the states and the FDA shenanigan, maybe Indonesia is actually a genius move from Recce! Diversification can only be good in the current climate.
Revenue following Indo approval is difficult to quantify. And given they *still* haven't even started the trial yet, months late already -- question marks remain around the timeline.
Directors are only taking *part* of their entitlement. It will be interesting to see how much....
RCE Price at posting:
28.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)